Efficacy and safety of gemcitabine plus S-1 vs. gemcitabine plus nab-paclitaxel in treatment-naïve advanced pancreatic ductal adenocarcinoma

Efficacy and safety of gemcitabine plus S-1 vs. gemcitabine plus nab-paclitaxel in treatment-naïve advanced pancreatic ductal adenocarcinoma

Objective: Gemcitabine plus nab-paclitaxel (GnP) is the standard first-line therapy for advanced pancreatic ductal adenocarcinoma (PDAC). S-1, an oral fluoropyrimidine derivative, as compared with gemcitabine, is non-inferior in terms of overall survival (OS) and is associated with lower hematologic...

Ful tanımlama

Detaylı Bibliyografya
Asıl Yazarlar: Zhou Zhu, Hui Tang, Jinrong Ying, Yuejuan Cheng, Xiang Wang, Yingyi Wang, Chunmei Bai
Materyal Türü: Makale
Dil:English
Baskı/Yayın Bilgisi: China Anti-Cancer Association 2023-10-01
Seri Bilgileri:Cancer Biology & Medicine
Konular:
advanced pancreatic cancer
first-line chemotherapy
gemcitabine
s-1
nab-paclitaxel
Online Erişim:https://www.cancerbiomed.org/content/20/10/765

Internet

https://www.cancerbiomed.org/content/20/10/765

Benzer Materyaller